Literature DB >> 12802586

Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q.

Ronald Boonstra1, Alice Koning, Mirjam Mastik, Anke van den Berg, Sibrand Poppema.   

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare disease. A small number of cytogenetic studies of PCNSL have been conducted and several reports have been published on associated molecular and protein expression data. We combined these approaches in a series of eight PCNSL cases, analyzing the chromosomal abnormalities using comparative genomic hybridization (CGH), testing for Epstein Barr virus (EBV) involvement by in situ hybridization for EBER, assessing expression of p53, Bcl-2, Bcl-6 and CD10 by means of immunohistochemistry, and screening for mutations of the TP53 gene by DGGE. TP53 gene mutations and EBV expression were not detected. Most of the cases showed p53, Bcl-6 and Bcl-2 protein expression. CGH revealed DNA copy number changes in all eight cases. The most frequent changes were gains of chromosome 12 (63%), chromosome 18 (50%) and 20q (38%), and loss of chromosome arm 6q (75%). No correlation between protein expression and chromosomal abnormalities was found in these eight cases. Although gains of chromosome 12, 18 and 20q and loss of 6q have also been reported in systemic diffuse large B-cell lymphomas, the frequency of 6q deletion is clearly higher in PCNSL. This creates a similarity to primary lymphomas of the testes that also frequently have deletions of 6q. This suggests that suppressor genes located on chromosome 6q may play a role in the development of lymphomas at immunoprivileged sites, like the CNS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12802586     DOI: 10.1007/s00428-003-0836-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  33 in total

1.  Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffin-embedded tissue.

Authors:  V M Hayes; W Bleeker; E Verlind; T Timmer; A Karrenbeld; J T Plukker; M P Marx; R M Hofstra; C H Buys
Journal:  Diagn Mol Pathol       Date:  1999-03

2.  Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry.

Authors:  K Harada; T Nishizaki; H Kubota; K Harada; M Suzuki; K Sasaki
Journal:  Cancer Genet Cytogenet       Date:  2001-03

3.  Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group.

Authors:  T R Coté; A Manns; C R Hardy; F J Yellin; P Hartge
Journal:  J Natl Cancer Inst       Date:  1996-05-15       Impact factor: 13.506

4.  Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.

Authors:  L Flenghi; B Bigerna; M Fizzotti; S Venturi; L Pasqualucci; S Pileri; B H Ye; M Gambacorta; R Pacini; C D Baroni; E Pescarmona; I Anagnostopoulos; H Stein; G Asdrubali; M F Martelli; P G Pelicci; R Dalla-Favera; B Falini
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

5.  Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989.

Authors:  D C Miller; F H Hochberg; N L Harris; M L Gruber; D N Louis; H Cohen
Journal:  Cancer       Date:  1994-08-15       Impact factor: 6.860

6.  Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type.

Authors:  T Weber; R G Weber; K Kaulich; B Actor; B Meyer-Puttlitz; S Lampel; R Büschges; R Weigel; M Deckert-Schlüter; P Schmiedek; G Reifenberger; P Lichter
Journal:  Brain Pathol       Date:  2000-01       Impact factor: 6.508

Review 7.  Classification, pathogenesis and molecular pathology of primary CNS lymphomas.

Authors:  W Paulus
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

8.  Increasing incidence of primary brain lymphoma in the US.

Authors:  N L Eby; S Grufferman; C M Flannelly; S C Schold; F S Vogel; P C Burger
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

Review 9.  p53 expression in non-Hodgkin's lymphomas: a marker of p53 inactivation?

Authors:  M A Piris; R Villuendas; J C Martinez; M Sanchez-Beato; J L Orradre; M S Mateo; P Martinez
Journal:  Leuk Lymphoma       Date:  1995-03

10.  p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time.

Authors:  M A Piris; F Pezzella; J C Martinez-Montero; J L Orradre; R Villuendas; M Sanchez-Beato; R Cuena; M A Cruz; B Martinez; F ] Pezella F [corrected to Pezzella
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

View more
  10 in total

Review 1.  Diagnosis and treatment of primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

Review 2.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

Review 3.  Introduction of novel agents in the treatment of primary CNS lymphoma.

Authors:  Christian Grommes; Lakshmi Nayak; Han W Tun; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

Review 4.  The Challenge of Primary Central Nervous System Lymphoma.

Authors:  Julia Carnevale; James L Rubenstein
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

5.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

Review 6.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

7.  Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.

Authors:  Francois M Cady; Brian Patrick O'Neill; Mark E Law; Paul A Decker; David M Kurtz; Caterina Giannini; Alyx B Porter; Paul J Kurtin; Patrick B Johnston; Ahmet Dogan; Ellen D Remstein
Journal:  J Clin Oncol       Date:  2008-07-21       Impact factor: 44.544

Review 8.  Progress in central nervous system lymphomas.

Authors:  Chia-Ching Wang; Julia Carnevale; James L Rubenstein
Journal:  Br J Haematol       Date:  2014-05-16       Impact factor: 6.998

9.  High-resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays.

Authors:  Ludan Wang; Aiko Sato-Otsubo; Sunao Sugita; Hiroshi Takase; Manabu Mochizuki; Yoshihiko Usui; Hiroshi Goto; Takatoshi Koyama; Hiroki Akiyama; Osamu Miura; Seishi Ogawa; Ayako Arai
Journal:  Cancer Sci       Date:  2014-04-01       Impact factor: 6.716

10.  Primary intracranial lymphomas.

Authors:  Shagufta T Mufti; Saleh S Baeesa; Jaudah A Al-Maghrabi
Journal:  Asian J Neurosurg       Date:  2016 Jul-Sep
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.